Novo Nordisk signs deal with OpenAI to develop new drugs

Danish pharmaceuticals group Novo Nordisk, maker of the popular Ozempic and Wegovy anti-obesity drugs, announced Tuesday a "strategic partnership" with OpenAI to accelerate the development of new medications.